Treatment of High-risk Myelodysplastic Syndrome

LI Shijun; QI Junyuan

doi:10.3971/j.issn.1000-8578.2020.20.0412

LI Shijun, QI Junyuan. Treatment of High-risk Myelodysplastic Syndrome[J]. Cancer Research on Prevention and Treatment, 2020, 47(12): 996-1002. DOI: 10.3971/j.issn.1000-8578.2020.20.0412

Citation:

LI Shijun, QI Junyuan. Treatment of High-risk Myelodysplastic Syndrome[J]. Cancer Research on Prevention and Treatment, 2020, 47(12): 996-1002. DOI: 10.3971/j.issn.1000-8578.2020.20.0412

Citation:

LI Shijun, QI Junyuan. Treatment of High-risk Myelodysplastic Syndrome[J]. Cancer Research on Prevention and Treatment, 2020, 47(12): 996-1002. DOI: 10.3971/j.issn.1000-8578.2020.20.0412

Treatment of High-risk Myelodysplastic Syndrome

Graphical Abstract

Graphical Abstract

Abstract

Abstract

Myelodysplastic syndrome (MDS) is a kind of hematological malignancies, characterized by malignant clones in hematopoietic stem cells. The treatment mainly focused on epigenetic treatment, chemotherapy, stem cell transplantation and new drugs. This article summarized all these kinds of treatments.

FullText(HTML)

References (42)

Cited By

Turn off MathJax

Article Contents

Treatment of High-risk Myelodysplastic Syndrome

Graphical Abstract

Abstract

Catalog

Export File

Citation

Format

Content